Healthcare News
Market coverage tagged Healthcare.
- Most Active
AbCellera ABCL-635 Cuts Menopause Hot Flashes 83% in Phase II Trial, Stock Surges 25%
AbCellera Biologics reported positive top-line four-week results from a Phase II trial of ABCL-635, a potential first-in-class once-monthly injectable antibody targeting the neurokinin 3…
- Top Mover
Eli Lilly's Oral Weight-Loss Pill Foundayo Wins First European Approval in the UK
Britain's Medicines and Healthcare products Regulatory Agency approved Eli Lilly's oral GLP-1 pill orforglipron, branded Foundayo, on August 10, making the UK the first European country to…
- Top Mover
Vertex Stock Hits All-Time High of $539.99 as Rival Sionna's CF Drug Fails Phase 2a Trial
Vertex Pharmaceuticals shares surged 5.9% to an all-time high of $539.99 on August 10 after Sionna Therapeutics disclosed that its cystic fibrosis drug candidate SION-719 missed the primary…
- Market Flux Event
Trump Signs Executive Order Cutting Recommended Childhood Vaccines to 11 and Splitting Up MMR Shot
President Trump signed an executive order on Monday, August 10, 2026, calling for a significant overhaul of the federal childhood vaccine schedule. The order narrows the administration's…
- Market Flux Event
Eli Lilly Wins UK Approval for Oral Weight-Loss Pill Foundayo as Biotech Sector Sees Wave of Catalysts
Eli Lilly's oral weight-loss pill orforglipron, branded Foundayo, secured its first European regulatory approval in Britain on August 10, extending the drug's commercial footprint beyond…
- Market Flux Event
Trump Signs Executive Order Cutting Recommended Childhood Vaccines from 18 to 11 Diseases and Splitting MMR Shot
President Trump signed an executive order Monday directing that the number of diseases for which all children are universally recommended to be vaccinated drop from 18 to 11. The order…
- Unusual Volume
Sionna Therapeutics Stock Crashes 92% After SION-719 Cystic Fibrosis Trial Fails Key Endpoint
Sionna Therapeutics shares plunged roughly 92% to a record low on August 10, 2026, after the company announced that SION-719, its first-in-class NBD1 stabilizer, missed the primary endpoint…
- Market Flux Event
Moderna Wins FDA Approval for First mRNA Flu Vaccine, Stock Response Muted
The FDA approved Moderna's seasonal flu vaccine, marking the first mRNA-based flu shot authorized in the U.S. Despite this milestone signaling potential post-pandemic growth, investor…